Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity

@article{Romero2008DiabetesinducedCV,
  title={Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity},
  author={Maritza Romero and Daniel H. Platt and Huda E. Tawfik and Mohamed Labazi and Azza B. El-Remessy and Manuela Bartoli and Ruth B. Caldwell and Robert W. Caldwell},
  journal={Circulation Research},
  year={2008},
  volume={102},
  pages={95-102}
}
Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with… Expand
Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production.
TLDR
Arginase inhibition alleviates hypertension in diabetes through a mechanism involving prevention of the impairment in endothelial dependent relaxation and NO production. Expand
Diabetes-induced vascular dysfunction involves arginase I.
TLDR
In diabetic WT and AI(+/-)AII (-/-) mice, aortic arginase activity and AI expression were significantly increased compared with control mice, but neither parameter was altered in AI( +/-) aorta, which indicates a major involvement of AI in diabetes-induced vascular dysfunction. Expand
Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1
TLDR
Vascular dysfunctions in diet-induced obesity are prevented or significantly reduced by endothelial-specific deletion of arginase 1 or ABH treatment, indicating that upregulation of arkinase 1 expression/activity in vascular endothelial cells has an integral role in food-induced cardiovascular dysfunction and metabolic syndrome. Expand
Hyperglycemia‐impaired aortic vasorelaxation mediated through arginase elevation: Role of stress kinase pathways
TLDR
Targeting this pathway may provide an effective means for preventing diabetes/hyperglycemia‐induced vascular endothelial dysfunction and activated ROCK and subsequent activation of ERK1/2 or p38 MAPK elevates arginase activity and Arg1 expression in hyperglycemic states. Expand
Plasma arginase activity is elevated in type 2 diabetic patients
TLDR
Results indicate that diabetic state causes an elevation of arginase activity which can limit EC production of NO and thus impairs vasorelaxation, and can be regarded as a novel marker for the vascular complications of diabetes. Expand
Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.
TLDR
Partial deletion of either ROCK isoform, but to a greater extent ROCK1, attenuates diabetes-induced vascular endothelial dysfunction by preventing increased arginase activity and expression and reduction in NO production in type 1 diabetes. Expand
Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats.
TLDR
Treatment with nor-NOHA restores the microvascular function by a mechanism related to increased utilization of arginine by NOS and increased NO availability, suggesting a shift ofArginine utilization from arginase to NOS. Expand
Arginase Promotes Skeletal Muscle Arteriolar Endothelial Dysfunction in Diabetic Rats
TLDR
The ability of arginase to induce endothelial dysfunction in skeletal muscle arterioles may further compromise glucose utilization and facilitate the development of hypertension in diabetes. Expand
Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus
TLDR
Inhibition of arginase protects against endothelial dysfunction caused by ischemia-reperfusion in patients with CAD and may thereby be a promising therapeutic strategy in the treatment of ischemIA-rePerfusion injury. Expand
Arginase Inhibition Improves Endothelial Function in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus
TLDR
Arginase inhibition markedly improves endothelial function in patients with CAD and type 2 diabetes mellitus suggesting that increased arginase activity is a key factor in the development of endothelial dysfunction. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Simvastatin Improves Diabetes-Induced Coronary Endothelial Dysfunction
TLDR
It is suggested that simvastatin improves diabetes-induced coronary dysfunction by reducing oxidative stress and increasing NO bioavailability. Expand
Amelioration by L‐Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic Endothelium
TLDR
It is shown that a mechanism for impaired endothelium-dependent relaxation to ACh in diabetic aorta may arise from a defect in utilization of L-Arg by NO synthase for production of EDRF/NO. Expand
Arginase Reciprocally Regulates Nitric Oxide Synthase Activity and Contributes to Endothelial Dysfunction in Aging Blood Vessels
TLDR
These findings demonstrate that arginase modulates NOS activity, likely by regulating intracellular l-arginine availability, and may therefore be a therapeutic target. Expand
Knockdown of Arginase I Restores NO Signaling in the Vasculature of Old Rats
TLDR
The hypothesis that Arg I plays a critical role in the pathobiology of age-related vascular endothelial dysfunction is supported and antisense (AS) oligonucleotides may, therefore, represent a novel therapeutic strategy against age- related vascular endothelium dysfunction. Expand
Upregulation of Vascular Arginase in Hypertension Decreases Nitric Oxide–Mediated Dilation of Coronary Arterioles
TLDR
No-mediated dilation of coronary arterioles is inhibited in hypertension by an increase in arginase activity in EC, which limits l-arginine availability to NOS for NO production. Expand
Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide‐mediated vasodilatory function
TLDR
Novel findings are provided that the arginase expressed in the endothelium plays a counteracting role in the stimulated NO production, and thus NO‐mediated vasodilatory function. Expand
Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease.
TLDR
Loss of .NO production in IBD microvessels is linked to enhanced levels of AR in intestinal endothelial cells exposed to chronic inflammation in vivo, and its contribution to decreased .NOProduction was characterized. Expand
Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production.
TLDR
A potential intracellular substrate deficiency in nitric oxide production by diabetic endothelium which can be overcome acutely in vitro by provision of substrate for Nitric oxide synthase is suggested. Expand
Effects of Dietary l-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilatationin the Hypercholesterolemic Rabbit
TLDR
Whether di-etary l-arginine, the precursor of NO, could chronically preserve endothelium-dependent vasodilatation in vivo and/or limit atherogenesis is examined. Expand
Oxidized Low-Density Lipoprotein–Dependent Endothelial Arginase II Activation Contributes to Impaired Nitric Oxide Signaling
TLDR
OxLDLs increase arginase activity by a sequence of regulatory events that involve early activation through decreased association with microtubules and a later increase in transcription, which contributes to OxLDL-dependent impairment of NOx production. Expand
...
1
2
3
4
5
...